Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:138798037" >
Rituximab in multip...
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
-
- Dunn, N (författare)
- Karolinska Institutet
-
- Juto, A (författare)
- Karolinska Institutet
-
Ryner, M (författare)
-
visa fler...
-
- Manouchehrinia, A (författare)
- Karolinska Institutet
-
Piccoli, L (författare)
-
- Fink, K (författare)
- Karolinska Institutet
-
- Piehl, F (författare)
- Karolinska Institutet
-
- Fogdell-Hahn, A (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2017-08-01
- 2018
- Engelska.
-
Ingår i: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1477-0970 .- 1352-4585. ; 24:9, s. 1224-1233
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Rituximab is a chimeric monoclonal anti-CD20 B-cell-depleting antibody increasingly used off-label in multiple sclerosis (MS). The clinical relevance of anti-drug antibodies (ADAs) against rituximab in MS is unknown. Objective: To determine frequency of ADA in relation to B-cell counts, allergic reactions and clinical efficacy in a large cohort of MS-treated patients. Methods: Cross-sectional study with collection of serum samples from 339 MS patients immediately before a scheduled rituximab infusion. ADAs were detected using an in-house–validated electrochemiluminescent immunoassay and a commercial enzyme-linked immunosorbent assay (ELISA) to compare methods. Data on patient demographics and clinical outcomes were retrieved from the Swedish MS Registry and patient records. Results: ADAs were detected in 37% of relapsing–remitting MS and 26% in progressive forms of MS. Presence of ADAs decreased with increasing number of rituximab infusions. There was a significant association between both presence and titres of ADAs and incomplete B-cell depletion, but not with infusion/adverse reactions or clinical outcomes at the group level. Only five patients terminated rituximab during follow-up, four of which were ADA positive. Conclusion: Rituximab treatment is associated with a high degree of ADAs, which correlates with efficacy of B-cell depletion; however, the clinical relevance of ADAs remains uncertain.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas